Terazosine [Inn-French] en es it fr

Terazosine [Inn-French] Brand names, Terazosine [Inn-French] Analogs

Terazosine [Inn-French] Brand Names Mixture

  • No information avaliable

Terazosine [Inn-French] Chemical_Formula


Terazosine [Inn-French] RX_link


Terazosine [Inn-French] fda sheet

Terazosine_[Inn-French] FDA

Terazosine [Inn-French] msds (material safety sheet)

Terazosine [Inn-French] Synthesis Reference

M. Winn et al., U.S. Pat. 4,026,894 (1977)

Terazosine [Inn-French] Molecular Weight

387.433 g/mol

Terazosine [Inn-French] Melting Point

273 oC

Terazosine [Inn-French] H2O Solubility


Terazosine [Inn-French] State


Terazosine [Inn-French] LogP


Terazosine [Inn-French] Dosage Forms


Terazosine [Inn-French] Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Terazosine [Inn-French] Pharmacology

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.

Terazosine [Inn-French] Absorption

Essentially completely absorbed in man (90% bioavailability).

Terazosine [Inn-French] side effects and Toxicity

LD50=259.3mg/kg (i.v. in mice)

Terazosine [Inn-French] Patient Information

Terazosine [Inn-French] Organisms Affected

Humans and other mammals